Sarepta Therapeutics, Inc.SRPT
ASignal's systematic analysis rates SRPT as Neutral.
Reflects the latest available analysis · analyzed Aug 19, 2026
The case on SRPT
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Positive MACD histogram indicating strengthening bullish momentum
- Current ratio of 4.42x suggests strong short-term liquidity
- Free cash flow positive at $22.14M
- Debt-to-equity ratio of 0.70x is moderate and manageable
- Forward P/E of 7.66x appears low relative to growth expectations
- RSI at 77.88 indicates overbought conditions
- Price trading above upper Bollinger Band (19.52) suggesting potential pullback
- Negative gross margin (-17.30%) reflects core business challenges
- Negative ROE (-9.48%) and negative profit margin (-6.93%)
- YoY revenue growth of -34.30% shows significant contraction
- EV/EBITDA at -124.18x due to negative earnings, limiting valuation appeal
See the full verdict on SRPT
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes SRPT
Most investors never get a second opinion, let alone several. ASignal runs SRPT past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.